Please ensure Javascript is enabled for purposes of website accessibility

Why Allakos Stock Is Crashing Today

By Keith Speights – Dec 22, 2021 at 10:41AM

Key Points

  • Allokos said that lirentelimab failed to meet co-primary endpoints in two clinical studies.
  • The company hopes to find a path forward for the drug in treating eosinophilic gastrointestinal diseases.
  • In the meantime, Allokos is continuing studies of the drug in treating other indications.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced disappointing results from two clinical studies.

What happened

Shares of Allakos (ALLK 1.61%) are crashing 88% lower as of 10:17 a.m ET on Wednesday. The huge decline came after the company announced results from its phase 3 Enigma 2 and its phase 2/3 Kryptos clinical studies evaluating lirentelimab.

Allakos reported that both clinical studies met their histologic co-primary endpoints. However, neither study achieved statistically significant improvement on patient-reported symptomatic co-primary endpoints.

Scientists with concerned expressions on their faces.

Image source: Getty Images.

So what

The biotech stock plunged so much because the co-primary endpoint misses weren't even close. That's especially problematic because lirentelimab is Allokos' only pipeline candidate in clinical development.

Patients in the Enigma 2 study who received a placebo reported a greater absolute change in the six-symptom total symptom score (TSS) than did patients receiving lirentelimab. It was a similar story with the Kryptos study with patients receiving a low dose of the drug. Patients receiving the high dose of lirentelimab reported greater improvement in symptoms than those on a placebo, but it wasn't enough to be statistically significant.

Allakos executives didn't try to spin the results as positive. CEO Robert Alexander said, "We are deeply disappointed that the studies did not achieve their symptomatic endpoints." Chief medical officer Craig Paterson called the results "surprising and disappointing."

Now what

Paterson stated that Allokos "at present" plans to continue analyzing the data from the two studies in an effort to determine a path forward for lirentelimab in treating eosinophilic gastrointestinal diseases. The company also plans to continue the development of a subcutaneous version of the drug targeting atopic dermatitis, asthma, and chronic spontaneous urticaria.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.